Valneva

Synopsis : Valneva’s single-shot chikungunya vaccine candidate, VLA1553, offered a very high level of seroprotection in all adults, including the elderly. The…

Summary : The Committee for Medicinal Products for Human Use (CHMP) has provided an initial assessment of Valneva’s inactivated, adjuvanted COVID-19 vaccine…

Synopsis : Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. (NYSE: PFE) today reported further positive…

Summary: -Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today confirms the previously communicated timelines of its clinical trials…